Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Abstract Background The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they may also cause genitourinary infections, polyuria,...

Full description

Bibliographic Details
Main Authors: Hiroki Nakajima, Sadanori Okada, Takako Mohri, Eiichiro Kanda, Naoyuki Inaba, Yoko Hirasawa, Hiroaki Seino, Hisamoto Kuroda, Toru Hiyoshi, Tetsuji Niiya, Hitoshi Ishii
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Type 2 diabetes mellitus
Oral hypoglycemic agent
Sodium glucose cotransporters 2 inhibitors
SGLT2 inhibitors
Dapagliflozin
Treatment satisfaction
Online Access:http://link.springer.com/article/10.1186/s13098-018-0313-x

Internet

http://link.springer.com/article/10.1186/s13098-018-0313-x

Similar Items